
Pastakia D, McCully C, Bacher J, Cole D, Druz R, Blakley J, et al. Comparison of intravenous microdialysis sampling to standard blood sampling to determine free etoposide exposure (AUC) in a non-human primate model [abstract]. Proc Am Assoc Cancer Res. 2010.
Kim A, McCully C, Cruz R, Cole D, Fox E, Balis F, et al. The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates [abstract]. Proc Am Assoc Cancer Res. 2010.
Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren K, et al. The plasma and cerebrospinal fluid pharmacokinetics of satraplatin after intravenous administration in non-human primates [abstract]. Proc Am Assoc Cancer Res; 2010.
2008, NIH Award of Merit for Transition of Carboxypeptidase Treatment Program
2006, NIH Director's Award of Merit for Contributions to Clinical Development of Treatment for Childhood Cancer
2002, ASCO Merit Award
2000, AACR-Glaxo Wellcome Oncology Scholar Award for Promising Clinical/Translational Research
1999, NCI Fellowship Training Award
1995, Feigin Scholar, Texas Children's Hospital
1991, Shapiro Scholar, Department of Pediatrics, University of Rochester
Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. 2nd ed. Burlington: Academic Press; 2006.
Fox E, Adamson PC. Future trends in cancer chemotherapy. In: Voute PA, Barrett A, Stevens, MCG, editors. Cancer in children clinical management. 5th ed. New York: Oxford University Press; 2005.
Fox E, Adamson PC. Phase I trial design considerations in the pediatric population. In: Budman DR, Calvert AH, Rowinsky EK, editors. Handbook of anticancer drug development. Philadelphia: Lippincott Williams & Wilkins; 2003.
Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2003.
Fox E, Balis FM. Drug therapy in newborns and children. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, editors. Principles of clinical pharmacology. Burlington: Academic Press; 2001.
2007-present, Associate Editor, Journal of the National Cancer Institute
Blood
Cancer Chemotherapy & Pharmacology
Cancer Research
Clinical Cancer Research
Journal of Clinical Oncology
Journal of the National Cancer Institute
Journal of Pediatric Hematology & Oncology
Journal of Pharmacology & Experimental Therapeutics
Pediatric Blood & Cancer
2008-present, NCI Seminar Series Organizational Committee, Pediatric Oncology Branch
2008-present, Children's Oncology Group Neuroblastoma Committee, Task Force for Study Design of Maintenance Therapy for High Risk Neuroblastoma
2008-present, Biomedical Research Information System Development Task Force Center for Cancer Research, NCI
2007-present, Pediatric Oncology Branch, NCI Web Development Committee
2006-present, Children's Oncology Group Neuroblastoma Committee
2006-present, Children's Oncology Group Trial Design and Endpoints in Neuroblastoma Task Force
2004-present, Center for Cancer Research Early Drug Development Committee
Children's Oncology Group Study Committees
2002-present, Children's Oncology Group
1998-present, American Society of Clinical Oncology
1997-present, American Association for Cancer Research
Fox E. Pharmacology & experimental therapeutics section network: educational series for pediatric hematology oncology fellows and pediatric residents, monthly live AdobeConnect™ chemotherapy and clinical pharmacology lectures to six institutions [online lecture].
Fox E. CHOP Division of Oncology educational web-based seminars series: monthly chemotherapy and clinical pharmacology lectures, Microsoft Live Broadcast to six pediatric oncology programs [online lecture].
Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, et al. Phase I trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb;56(2):226-33. doi: 10.1002/pbc.22775. Epub 2010 Sep 21. Cited in PubMed: PMID 20860038. Read the abstract
Chuk MK, Cole D, McCuly CL, Loktionova N, Pegg A, Pauly G, et al. Plasma and CND pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model. Cancer Chemother Pharmacol. 2011 Jun;67(6):1291-7. Epub 2010 Aug 20. Cited in PubMed: PMID 20725726. Read the abstract
Lipsitz E, Moorthy G, Mosse Y, Fox E, Adamson PC. A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma. J Chromatogr B. 2010 Sep 1;878(25):2369-73. Epub 2010 Jul 3. Cited in PubMed: PMID 20685183. Read the abstract
Fox E, Aplenc R, Chuk M, Widemann BC, Bagatell R, Goodspeed W, et al. Phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor in children and adolescents with refractory solid tumors. J Clin Oncol. 201 Dec 10;28(35):5174-81. Epub 2010 Nov 8. Cited in PubMed: PMID 21060028. Read the abstract
Fox E, Jayaprakash N, Pham T-H, Rowley A, McCully C, Pucino F, Goldbach-Mansky R. The serum and cerebrospinal fluid pharmacokinetics of anakinra after intravenous administration to non-human primates. J Neuroimmunol. 2010 Jun;223(1-2):138-40. Epub 2010 Apr 24. Cited in PubMed: PMID 20421138. Read the article
Widemann BC, Balis FM, Kim A, Boron M, Jayaprakash N, Shalabi A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate induced renal dysfunction: clinical and pharmacologic factors impacting outcome. J Clin Oncol. 2010 Sep 1, 28(25):3979-86. Epub 2010 Aug 2. Cited in PubMed: PMID 20679598. Read the abstract
Paoloni M, Mazcko C, Fox E, Fan T, Lana S, Kisseberth W, et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 5(6):e11013. Cited in PubMed: PMID 20543980. Read the article
Meany H, Balis FM, Aikin A, Whitcomb P, Murphy R, Steinberg S, et al. Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst. 2010 Jun 16;102(12):909-12. Epub 2010 May 11. Cited in PubMed: PMID 2046032. Read the article
Fox E, Maris JM, Cohn JM, Goodspeed W, Goodwin A, Kromplewski M, et al. Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. Cancer Chemother Pharmacol. 2010 Sep;66(4):737-43. Epub 2010 Jan 1. Cited in PubMed: PMID 20044751. Read the abstract
Jacobs S, Fox E, Krailo MD, Hartley G, Navid F, Wexler L, et al. Phase II trial of ixabepilone (BMS-247550) in children and young adults with refractory solid tumors: a report from the Children's Oncology Group. Clin Cancer Res. 2010 Jan 15;16(2):750-4. Epub 2010 Jan 12. Cited in PubMed: PMID 20068084. Read the article
Meany HJ, Sackett DI, Maris JM, Ward Y, Krivoshik A, Cohn SL, et al. Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and tubulin polymerization in vitro. Pediatr Blood Cancer. 2010 Jan;54(1):47-54. Cited in PubMed: PMID 19731320. Read the article
« Back to Previous Page